The data revealed that patients receiving SNG001, an inhaled form of interferon beta medicine, had a 79 per cent lower risk of developing severe symptoms of the disease.
SMALL CAP MOVERS: Synairgen sees boost from Covid trial
Something you may find interesting…
[recent_products per_page="4" columns="4" orderby="rand" order="rand"]
Recent Comments